NovoCure (NVCR) EBIT Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -20.56% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 11.83% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -11.06% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 19.54% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 20.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 74.18% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 90.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -18.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 46.60% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -78.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.05% |
| Dec 31, 2025 | 36.19% |
| Sep 30, 2025 | -12.24% |
| Jun 30, 2025 | -17.69% |
| Mar 31, 2025 | 8.80% |
| Dec 31, 2024 | -22.41% |
| Sep 30, 2024 | 44.90% |
| Jun 30, 2024 | 46.41% |
| Mar 31, 2024 | 31.09% |
| Dec 31, 2023 | -20.33% |
| Sep 30, 2023 | -136.66% |
| Jun 30, 2023 | -196.57% |
| Mar 31, 2023 | -7,375.06% |
| Dec 31, 2022 | -83.68% |
| Sep 30, 2022 | -187.78% |
| Jun 30, 2022 | -71.84% |
| Mar 31, 2022 | -815.91% |
| Dec 31, 2021 | -293.50% |
| Sep 30, 2021 | -156.93% |
| Jun 30, 2021 | -284.39% |
| Mar 31, 2021 | 97.40% |
| Dec 31, 2020 | 7,803.27% |
| Sep 30, 2020 | 289.68% |
| Jun 30, 2020 | 457.53% |
| Mar 31, 2020 | 44.74% |
| Dec 31, 2019 | 101.77% |
| Sep 30, 2019 | 173.48% |
| Jun 30, 2019 | 116.88% |
| Mar 31, 2019 | 51.74% |
| Dec 31, 2018 | -92.28% |
| Sep 30, 2018 | 11.37% |
| Jun 30, 2018 | 54.38% |
| Mar 31, 2018 | 5.20% |
| Dec 31, 2017 | 74.79% |
| Sep 30, 2017 | 79.06% |
| Jun 30, 2017 | 58.29% |
| Mar 31, 2017 | 58.13% |
| Dec 31, 2016 | 41.59% |
| Sep 30, 2016 | -16.61% |
| Jun 30, 2016 | -36.87% |
| Mar 31, 2016 | -45.53% |
| Dec 31, 2015 | -33.02% |
| Sep 30, 2015 | -35.37% |